General Announcement::Glenmark receives approval for Tadalafil Tablets,Gabapentin Enacarbil Tablets and Apremilast Tablets

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
31-Dec-2020 13:34:37
Status
New
Announcement Sub Title
Glenmark receives approval for Tadalafil Tablets,Gabapentin Enacarbil Tablets and Apremilast Tablets
Announcement Reference
SG201231OTHRVQ5O
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
31/12/2020 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals receives ANDA final approval for Tadalafil Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg;and receives ANDA tentative approvals for Gabapentin Enacarbil Extended-Release Tablets, 300 mg and 600 mg and Apremilast Tablets, 10 mg, 20 mg and 30 mg

Attachments

SGX_PR_31122020.pdf
Total size =822K